About Vitti Long Haul
People experiencing persistent COVID-19 symptoms and pulmonary complications may benefit from continued clinical research and innovative treatment development. Vitti Long Haul is studying VL-PX10 and VL-P22, proprietary combination therapies based on mesenchymal stem cells, exosomes, and biomaterials. Both treatments are currently being evaluated in Phase 2 human clinical trials. A physician-led Expanded Access Program may offer another pathway for eligible patients who are unable to participate in clinical studies.